Wednesday, March 09, 2022 7:42:00 AM
Regarding egfr which was what you were asking about if not a typo, my guess is a solid "maybe". BID dosing did not seem to make much of a difference in HER2 first line but could it be that these patients are a lot less sicker and able to stomach the once daily 16mg dose much easier than a second or third line patient which was the case in cohort 1? If that is the case and a much sicker 2nd or 3rd line patient is able to stay on BID dosing longer that might make a considerable difference in efficacy and boost it over 20% from the 14.8% we saw in cohort 1. Also w cohort 1 there was, I suspect, a big learning curve in how to administer the drug which won't be the case if they run another trial. Hopefully, we'll get better color after the quarterly CC later this month.
Recent SPPI News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/09/2023 10:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/28/2023 04:15:27 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/26/2023 09:23:08 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM